Sopik Victoria, Sun Ping, Narod Steven A
Women's College Research Institute, 76 Grenville Street, Toronto, ON, M5S 1B2, Canada.
Breast Cancer Res Treat. 2017 Sep;165(2):391-402. doi: 10.1007/s10549-017-4333-2. Epub 2017 Jun 10.
To estimate the prognostic impact of estrogen receptor (ER)-status among women with primary invasive breast cancer, according to age at diagnosis.
We studied 1910 women with primary invasive breast cancer (stages I-III) who were treated at Women's College Hospital between 1987 and 2000. For each patient, we obtained information on age at diagnosis, tumour size, lymph node status, ER-status, treatments received (radiotherapy, chemotherapy and tamoxifen) and dates and causes of death. Patients were followed from the date of diagnosis until the date of death from breast cancer or the date of last follow-up. We used the Kaplan-Meier method to estimate the 15-year actuarial rates of breast cancer-specific survival for women with ER-positive and ER-negative breast cancer, according to age at diagnosis (categories). We used the Cox proportional hazards model to estimate the adjusted hazard ratios for death from breast cancer associated with positive ER-status (compared to negative ER-status), stratified by age at diagnosis.
We identified 1347 women with ER-positive breast cancer (70.5%) and 563 women with ER-negative breast cancer (29.5%). Among all 1910 women in the cohort, the actuarial rate of breast cancer-specific survival at 15 years was 77% for those with ER-positive breast cancer compared to 70% for those with ER-negative breast cancer (adjusted HR = 0.69; 95% CI 0.56-0.85; p = 0.0006). The prognostic impact of ER-status differed according to age at diagnosis. Among 213 women diagnosed before age 40, breast cancer-specific survival at 15 years was worse for those with ER-positive breast cancer than for those with ER-negative breast cancer (55 vs. 61%; adjusted HR = 0.90; 95% CI 0.57-1.41; p = 0.64). In contrast, among 1697 women diagnosed between ages 40 and 75, breast cancer-specific survival at 15 years was better for those with ER-positive breast cancer than for those with ER-negative breast cancer (78 vs. 72%; adjusted HR = 0.60; 95% CI 0.47-0.76; p < 0.0001).
Positive ER-status is a favourable prognostic factor among women diagnosed with breast cancer at or above age 40, but not among women diagnosed before age 40.
根据诊断时的年龄,评估雌激素受体(ER)状态对原发性浸润性乳腺癌女性患者预后的影响。
我们研究了1987年至2000年间在女子学院医院接受治疗的1910例原发性浸润性乳腺癌(I - III期)女性患者。对于每位患者,我们获取了诊断时的年龄、肿瘤大小、淋巴结状态、ER状态、接受的治疗(放疗、化疗和他莫昔芬)以及死亡日期和原因等信息。患者从诊断日期开始随访,直至因乳腺癌死亡或最后一次随访日期。我们使用Kaplan - Meier方法,根据诊断时的年龄(分类)估计ER阳性和ER阴性乳腺癌女性患者15年的乳腺癌特异性生存率。我们使用Cox比例风险模型估计与ER阳性状态(与阴性状态相比)相关的乳腺癌死亡调整风险比,并按诊断时的年龄分层。
我们确定了1347例ER阳性乳腺癌女性患者(70.5%)和563例ER阴性乳腺癌女性患者(29.5%)。在该队列的所有1910名女性中,ER阳性乳腺癌患者15年的乳腺癌特异性生存率为77%,而ER阴性乳腺癌患者为70%(调整后的风险比 = 0.69;95%置信区间0.56 - 0.85;p = 0.0006)。ER状态的预后影响因诊断时的年龄而异。在40岁之前诊断的213名女性中,ER阳性乳腺癌患者15年的乳腺癌特异性生存率低于ER阴性乳腺癌患者(55%对61%;调整后的风险比 = 0.90;95%置信区间0.57 - 1.41;p = 0.64)。相比之下,在40岁至75岁之间诊断的1697名女性中,ER阳性乳腺癌患者15年的乳腺癌特异性生存率高于ER阴性乳腺癌患者(78%对72%;调整后的风险比 = 0.60;95%置信区间0.47 - 0.76;p < 0.0001)。
ER阳性状态是40岁及以上诊断为乳腺癌的女性患者的有利预后因素,但在40岁之前诊断的女性患者中并非如此。